Amarin (AMRN) has been re-defining the omega-3 market with last year's REDUCE-IT results, wherein they demonstrated that addition of Vascepa led to a 25% relative risk reduction in onset of first major cardiovascular event vs statin monotherapy. This was followed by a recent FDA label expansion for Vascepa, which significantly increased its addressable market. Meanwhile, Acasti (ACST) has been riding on the coattail of AMRN's results and has been witnessing significant share price appreciation over the past year.
Figure 1. Recent closing prices for ACST.
For unclear reasons,